Future perspectives: Agents on the horizon

Jose R. Maya, Mohammad Ali Sadiq, Aniruddha Agarwal, Peter K. Kaiser, Glenn L. Stoller, Yasir Jamal Sepah, Quan Dong Nguyen

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalDevelopments in Ophthalmology
Volume55
DOIs
Publication statusPublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Maya, J. R., Sadiq, M. A., Agarwal, A., Kaiser, P. K., Stoller, G. L., Sepah, Y. J., & Nguyen, Q. D. (2015). Future perspectives: Agents on the horizon. Developments in Ophthalmology, 55, 391-398. https://doi.org/10.1159/000439037